Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. has announced the approval of their Investigational New Drug application for WJ47156 tablets, used in clinical trials for advanced malignant tumors treatment. The drug, JS125, is a selective inhibitor targeting histone deacetylases (HDACs), which play a role in tumor development and treatment. Investors are cautioned of the inherent high-risk nature of pharmaceutical development and encouraged to consider the investment risks carefully.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.